VISION2

ForSight Newco II (ForSight VISION2) is developing a proprietary ocular punctal plug drug delivery system. Punctal plugs are a non-invasive drug delivery system capable of delivering a variety of drugs to the eye over time through controlled release to the tear film. Sustained release punctal plugs could potentially replace eye drops for glaucoma, dry eye, allergies and postoperative care, which represent a $6 billion market. In addition, plugs may provide a more effective, convenient and reliable treatment alternative that could ultimately improve patient compliance with their medication and outcomes for their disease.

ForSight Newco II was acquired by and became a wholly-owned subsidiary of QLT, Inc. in October of 2007.